Elsevier

Cancer Treatment Reviews

Volume 27, Issue 6, December 2001, Pages 351-363
Cancer Treatment Reviews

Regular Article
Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine

https://doi.org/10.1053/ctrv.2002.0245Get rights and content

Abstract

Across the world, therapy with 6-mercaptopurine (6-MP) and methotrexate (MTX) forms the basis of the continuing therapy of childhood acute lymphoblastic leukaemia (ALL). In this review, the pharmacological determinants of the sensitivity of human leukaemia cell lines and lymphoblasts derived from children with ALL will be discussed. In addition, clinical pharmacological studies of 6-MP and MTX in relation to the continuing therapy with childhood ALL will be reviewed. For 6-MP in vitro, prolonged exposure times to relatively high extracellular drug concentrations are necessary for cytotoxicity, and these concentrations are much higher than those achieved during continuing therapy for childhood ALL. For MTX, plasma concentrations are achieved during continuing therapy that would be cytotoxic to human leukaemia cells during prolonged exposures in vitro. For both MTX and 6-MP, wide inter- and intrapatient variation in plasma pharmacokinetic parameters has been described. For 6-MP and MTX, cellular pharmacological studies have been largely restricted to erythrocytes as a surrogate of the possible effects in leukaemic blasts. Although measures of the pharmacology of 6-MP and MTX in erythrocytes has been related to prognosis in many studies, 6-MP systemic exposure and the dose intensity of 6-MP and MTX actually received by children during this phase of therapy seems to be the most important determinant of efficacy. Further studies will be needed to determine the importance of pharmacokinetic variability during continuing therapy as a determinant of outcome for children with ALL. In this respect, minimal residual disease status during this phase of treatment may prove to be a useful pharmacodynamic endpoint.

References (90)

  • HL McLeod et al.

    Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukaemic blasts from children with acute lymphoblastic leukaemia

    Blood

    (1995)
  • DE McCloskey et al.

    Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines

    J Biol Chem

    (1991)
  • R Gorlick et al.

    Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphoblastic leukaemia and is associated with decreased reduced folate carrier expression

    Blood

    (1997)
  • LH Matherly et al.

    Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukaemia in children

    Blood

    (1997)
  • VM Whitehead et al.

    Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukaemia: A pilot prognostic factor analysis

    Blood

    (1990)
  • VM Whitehead et al.

    Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukaemia: a Pediatric Oncology Group Study

    Blood

    (1992)
  • VM Belkov et al.

    Reduced folate carrier expression in acute lymphoblastic leukaemia, a mechanism for pliody but not lineage differences in methotrexate accumulation

    Blood

    (1999)
  • T Giverhaug et al.

    Increased concentrations of methylated 6-mercaptopurine metabolites and 6-thioguanine nucleotides in human leukaemic cells in vitro by methotrexate

    Biochem Pharmacol

    (1998)
  • Y Kato et al.

    Dose-dependent kinetics of orally administered6-mercaptopurine in children with leukaemia

    J Pediatrics

    (1991)
  • FM Balis et al.

    Pharmacokinetics and pharmacodynamics of methotrextare and mercaptopurine in children with lower risk acute lymphoblastic leukaemia: A joint Children's Cancer Group and Pediatric Oncology Branch study

    Blood

    (1998)
  • E Frei et al.

    Studies of sequential and combination antimetabolite therapy in acute leukaemia: 6-mercaptopurine and methotrexate

    Blood

    (1961)
  • EJ Freireich et al.

    The effect of 6-mercaptopurine on the duration of steroid-induced remissions in acute leukaemia: A model for evaluation of other potentially useful therapy

    Blood

    (1963)
  • E Frei et al.

    The effectivess of combinations of antileukaemic agents in inducing and maintaining remission induction in children with acute leukaemia

    Blood

    (1965)
  • MV Relling et al.

    Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukaemia

    Blood

    (1999)
  • SA Coulthard et al.

    The relationship between thiopurine methyltransferase activity and genotype in blasts form patients with acute leukaemia

    Blood

    (1998)
  • R Pieters et al.

    Relation of 5′-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukaemia

    Leukaemia Res

    (1992)
  • L Lennard et al.

    Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

    Lancet

    (1990)
  • JS Lilleyman et al.

    Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia

    Lancet

    (1994)
  • E Frei et al.

    Studies of sequential and combination antimetabolite therapy in acute leukaemia: 6-mercaptopurine and methotrexate

    Blood

    (1961)
  • J JM van Dongen et al.

    Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

    Lancet

    (1998)
  • JV Simone

    Optimal current treatment of childhood acute lymphoblastic leukaemia

    Cancer Treat Rep

    (1981)
  • WA Bleyer et al.

    Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukaemia: a report of the CCG-161 study by the Children's Cancer Study Group

    J Clin Oncol

    (1991)
  • A JP Veerman et al.

    High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukaemia: Results of protocol ALL VI form the Dutch Childhood Leukaemia Study Group

    J Clin Oncol

    (1996)
  • DH Mahoney et al.

    Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukaemia: A Pediatric Oncology Group Phase III trial

    J Clin Oncol

    (1998)
  • VJ Land et al.

    Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukaemia; a Pediatric Oncology Group study

    J Clin Oncol

    (1994)
  • JB Nachman et al.

    Augmented post-induction therapy for children with high-risk acute lymphoblastic leukaemia and a slow response to initial therapy

    N Engl J Med

    (1998)
  • OB Eden et al.

    Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)

    Br J Haematol

    (1991)
  • GB Elion

    The purine path to chemotherapy

    Science

    (1989)
  • Y Natsumeda et al.

    Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues

    Cancer Res

    (1984)
  • EY Krynetski et al.

    Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase

    Mol Pharmacol

    (1995)
  • BS Tay et al.

    Inhibition of phosphoribosyl pyrophosphate amidotransferase form Erlich ascites-tumour cells by thiopurine nucleotides

    Biochem Pharmacol

    (1968)
  • KR Hande et al.

    Purine antimetabolites

  • S Zimm et al.

    Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines

    Cancer Res

    (1985)
  • YH Ling et al.

    Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase and endonuclease function

    Mol Pharmacol

    (1992)
  • D Fink et al.

    The role of DNA mismatch repair in drug resistance

    Clin Cancer Res

    (1998)
  • Cited by (0)

    f1

    Correspondence to: Dr E. J. Estlin, Department of Paediatric Oncology, Royal Manchester Children's Hospital, Pendlebury, Manchester M27 4HA, UK, Tel.: 01617272950; Fax: 01617283529; E-mail:[email protected]

    View full text